| HIG |
Report |
Core EPS |
BEAT |
pred ~$3.32 vs. cons ~$3.18 |
MEDIUM |
| HIG |
Report |
Business Insurance underlying combined ratio |
IN-LINE |
pred ~89.4 vs. cons ~89.5 |
MEDIUM |
| HIG |
Report |
Consolidated net investment income (pre-tax) |
BEAT |
pred ~$755M vs. cons ~$725M |
MEDIUM |
| HIG |
Guide |
Business Insurance ex-comp renewal written price change (FY2026) |
UNCHANGED |
guide ~6% vs. cons ~5.5% (FY2026) |
MEDIUM |
| HIG |
Guide |
Employee Benefits full-year core margin |
LOWER |
guide ~7.0-7.5% vs. cons ~8.0% (FY2026) |
MEDIUM |
| HIG |
Guide |
Full-year net investment income growth |
BETTER |
guide ~+8-10% vs. cons ~+6% (FY2026) |
LOW |
| HIG |
Guide |
Capital return / buyback pace |
UNCHANGED |
guide ~$450M buyback vs. cons ~$450M (Q2/quarterly) |
MEDIUM |
| HIG |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| HIG |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
Even with a modest headline EPS beat driven by NII/alternatives, the print lands against the toughest comp of the year (Q2'25 $3.41 core EPS, 9.2% EB margin, $163M favorable PYD, benign CATs) into a stock near highs at ~1.9x book with 20% ROE — expectations are elevated (recall the ~3.7% drop after the Q1 beat). The debate items (softening commercial pricing, EB/disability and workers'-comp margin normalization, peak-season convective CAT risk, and lumpy PYD that won't repeat) drive implicit out-period cuts, so favorable-development-flattered EPS gets discounted and forward estimates drift lower, extending the initial negative reaction rather than reversing it. |
LOW |